Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
about
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisManaging Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsHow ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology GroupThe Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.Ruxolitinib for myelofibrosis--an update of its clinical effects.Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsRuxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsRuxolitinib: a review of its use in patients with myelofibrosis.Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.Practical management of myelofibrosis with ruxolitinib.Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesProteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasmsTreatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs SurvivalCreating clinical trial designs that incorporate clinical outcome assessments.Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsisLow-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsPatient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.The new landscape of therapy for myelofibrosis.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Jak-2 positive myeloproliferative neoplasms.STAT3 inhibitors: finding a home in lymphoma and leukemia.Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
P2860
Q24186554-A0CCECFB-289B-4BAC-9CA2-97CB9A1428A8Q26750696-5CDF6570-05CA-4193-8A03-C7BA875B54ACQ26779929-51592BEA-9D26-4871-9B2E-1C47E3067D6EQ26996258-4B9BB471-411A-45F5-8413-AF87871E3578Q28073296-B356D914-1A96-457F-A210-BB4795018B76Q30240043-BFF3A40F-869B-4A77-AB36-E863406E9F66Q30677640-2E0B798A-6BBE-4D71-B178-01E9B59453D7Q30964688-37AF4EA1-F596-4323-ADD5-E3DA871295EAQ33410346-06503E02-FA0D-4AE6-9562-199E2B63BD14Q33411502-731B2409-6396-4737-973E-1EF5E1BBA300Q33411755-002E6AEA-DEFF-4F6F-A918-588F59278E03Q33417217-7F165823-AD3A-4ACB-9BE9-1EBE81E9D0D1Q33419865-2F97AE54-AA38-44C1-96BA-4896F3E9C6FEQ33419957-822A4CE1-E49B-4ED6-86B4-5373B23226DAQ33420095-AC373598-2017-49C7-8242-7D122D76EDE7Q33421596-D33116F5-C808-4AE1-8679-6A3E68397891Q33428259-5117EAA3-C540-4989-9BFF-6E8ED9BA6EDAQ33436345-4E1A97E6-4DF2-4ABF-837F-0BF1EA94407AQ33436870-967EFD80-14AA-4436-9BF7-44075A657B67Q33705743-EE1F69F8-FD20-4DE4-9B7A-4DD4CF558319Q34477649-0E6B0321-F0F4-4C84-AAC1-172B538DE835Q35565555-FB0E9E58-F00D-4FBC-A6CC-E326A8F2BC8CQ35841839-17B447BC-786B-4812-BB5F-6508567AD33BQ36290517-34A610A6-71AA-4BB8-B62B-09B1266258C9Q36698168-1B08FE58-0256-4857-A148-3232C8FEBFA3Q36829883-36B286CF-C89C-49BC-B8FD-C68535D9E6BCQ36894603-1E999E5E-B785-417D-806A-069D66F71B98Q37035925-AB98A478-AC46-4607-936F-7549EBA94566Q37168138-D75F9220-B15A-4E32-9F7E-DA2FF7485545Q37217253-4F96042F-DA0A-49AC-A8CF-E9F333D5A8DDQ37561170-32989822-38A5-470C-8445-309F77BB4B0CQ38106623-F125F7C6-C53A-4460-9F93-A778E4C78836Q38150261-6745FB44-9B3D-4530-B9CF-0D3A5E79555BQ38187674-7E445A68-3C46-40C6-ACCF-E1919A6EE7E3Q38187675-5E3C7F6E-297D-4093-BCD3-894700FCA1CEQ38195778-271C0C72-7FB9-4AAD-984C-E1D0522B3272Q38202556-65A5F366-686B-429D-B5E3-C08929D6ED85Q38244843-BAC1BB2F-AE74-485E-A889-A4FDAC30B65CQ38267888-BE2F4CF9-A271-4205-AB90-4ADFD481D03EQ38341625-E6D93435-967D-40DE-87BC-854AA6166A3E
P2860
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@ast
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@en
type
label
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@ast
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@en
prefLabel
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@ast
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@en
P2093
P2860
P356
P1476
Effect of ruxolitinib therapy ...... ind, placebo-controlled trial.
@en
P2093
Alan L Shields
Carole B Miller
Elliott F Winton
Jason Gotlib
Jimmie H Harvey
John V Catalano
Michael W Deininger
Moshe Talpaz
Richard S Levy
Richard T Silver
P2860
P304
P356
10.1200/JCO.2012.44.4489
P407
P577
2013-02-19T00:00:00Z